| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Molecular Templates Inc. | Evofosfamide | Cancer - soft tissue sarcoma (406 trial) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Evofosfamide MAESTRO | Cancer - Pancreatic | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Evofosfamide | Cancer - soft tissue sarcoma (406 trial) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Evofosfamide MAESTRO | Cancer - Pancreatic | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | MT-3724 | Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Tarloxotinib | Cancer - Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Evofosfamide | Cancer - second line NSCLC | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Molecular Templates Inc. | Tarloxotinib | Cancer - mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |